Stock Analysis on Net

Moderna Inc. (NASDAQ:MRNA)

$24.99

Common-Size Income Statement
Quarterly Data

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Moderna Inc., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Net product sales
Cost of sales
Gross profit (loss)
Other revenue
Research and development
Selling, general and administrative
Income (loss) from operations
Interest income
Other income (expense), net
Income (loss) before income taxes
(Provision for) benefit from income taxes
Net Income (loss)

Based on: 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Income statement item Description The company
Income (loss) from operations The net result for the period of deducting operating expenses from operating revenues. Moderna Inc. income (loss) from operations as a percentage of net product sales decreased from Q4 2023 to Q1 2024 but then slightly increased from Q1 2024 to Q2 2024.
Income (loss) before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Moderna Inc. income (loss) before income taxes as a percentage of net product sales decreased from Q4 2023 to Q1 2024 but then slightly increased from Q1 2024 to Q2 2024.
Net Income (loss) The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Moderna Inc. net Income (loss) as a percentage of net product sales decreased from Q4 2023 to Q1 2024 but then slightly increased from Q1 2024 to Q2 2024.